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Since the discovery of the atrial natriuretic factor (ANF) an endocrine function has been 
attributed to the mammalian heart. This function may include definition of optimal 
conditions for efficient performance of the heart, e.g. by reduction of afterload in 
hypertension or of preload and afterload in heart failure. Plasma ANF levels were 
measured in various cardiovascular disease states and compared with those of controls 
and of patients with liver cirrhosis. Plasma ANF levels in hypertensive patients were 
sevenfold higher than in controls, and in patients with heart failure 40-fold higher than 
normal values. Small differences were detected between controls and patients with 
cirrhosis of the liver, in spite of the impaired renal sodium handling seen in cirrhotics. 
Plasma ANF levels were significantly correlated with haemodynamic parameters and 
were inversely related to the cardiac index. Treatment with an angiotensin converting 
enzyme inhibitor led to a significant decrease in plasma ANF levels in parallel with the 
haemodynamic improvement. Preliminary chromatographic analysis suggested 
differences in the structure of plasma ANF between normotensive and hypertensive 
subjects. 
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Introduction 
It has long been recognized that volume expansion 
increases the concentration of natriuretic agents in the 
plasma, enhances the Na+K+ATPase inhibitory activity of 
plasma and causes vasoconstriction [1,2]. These changes 
are thought to be the result of a change in the 
concentration of one or more substances in the plasma, 
provisionally termed 'natriuretic hormone'. 
Atrial natriuretic factors have now emerged as the first 
convincing candidates for the natriuretic hormone'. They 
comprise a family of naturally occurring peptides [2] with 
natriuretic and diuretic properties [3]. However, ANF 
does not influence Na+K+ATPase activity [4] and causes a 
vasodilation [5,6], suggesting that natriuresis and 
Na+K+ATPase inhibitory activity may not be caused by the 
same substance. 
Atrial natriuretic factors are synthesized by atrial 
myocytes, stored in specific granules [7] and released into 
the circulation upon volume or pressure loading [8]. 
Their effects may be mediated at specific peripheral 
From the Departments of Medicine I and II*. Ludwig-Maximilian-
University, Klinikum Grosshadern, D-8000 Munich, Federal 
Republic of Germany. 
binding sites following release into the systemic 
circulation [9]. By conventional criteria these polypep-
tides may be regarded as hormones, which implies that 
an endocrine function can be attributed to the 
mammalian heart. This endocrine function may include 
the definition of optimal conditions for efficient cardiac 
performance, e.g. by reduction of preload and afterload 
in heart failure or of afterload in hypertension. 
By the combined use of a sensitive radio-immunoassay 
and a series of chromatographic techniques, we have 
recently been able to demonstrate the occurrence in 
human plasma of authentic α-ANF, the 28-amino-acid 
C-terminal portion of the human precursor hormone 
pre-pro-ANF [10]. 
To assess the possible role of this novel hormone in 
cardiovascular physiology and volume homeostasis, 
plasma levels of immunoreactive ( ir ) ANF were measured 
in patients with cardiovascular disease, before and after 
pharmacological intervention, and in patients with 
abnormal renal sodium handling due to cirrhosis of the 
liver. 
Requests for reprints to: Dr R.Arendt, Department of Medicine I, 
Ludwig-Maximilian-University, Klinikum Grosshadern, D-8000 
Munich, Federal Republic of Germany. 
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Methods 
Radio-immunoassay 
A radio-immunoassay was developed by conventional 
techniques, as described previously [10]. Briefly, a 
polyclonal antibody was raised against α-human 
(α-h) ANF (Nova Biochem, Switzerland), the 28-amino-
acid residue portion of the human precursor-ANF. 
^i-alpha-human ANF was prepared by the chloramine 
Τ method. The final antibody dilution in the radio­
immunoassay was 1:35 000. Separation of bound and free 
hormone following overnight incubation at 5°C was 
achieved by activated charcoal suspension. 
Sample collection and plasma extraction 
Peripheral blood was drawn into pre-cooled 20-ml 
syringes and immediately transferred to pre-cooled 
polystyrene tubes containing 500 KIU/ml aprotinin and 1 
mg/ml sodium ethylenediaminetetracetic acid. Plasma 
was separated and stored at — 70°C until extraction. 
Extraction was performed by adsorption to Amberlite 
XAD-2 adsorbent resin (particle size 0.3-1.0 mm; Serva, 
Heidelberg, Federal Republic of Germany) and adsorbed 
ANF was eluted with 55% acetonitrile in 0.1 mol/1 acetic 
acid. The extraction recovery was 68% and was 
independent of the concentration in the range 6-200 
fmol/ml; plasma values were not corrected for recovery. 
Eluates were lyophilized and either redissolved in buffer 
for radio-immunoassay or subjected to chromatographic 
analysis. 
Chromatography 
High performance gel permeation chromatography of 
plasma extracts was performed on a TSK-125 Bio Sil 
column (7.5 x 600 mm: Bio Rad. Munich. Federal 
Republic of Germany) eluted with 0.09% trifluoroacetic 
acid containing 0.005 mol/1 Na 2S0 4 plus 0.002 mol/1 
NaH 2 P0 4 and 30% acetonitrile, as a solvent. The flow rate 
was 0.4 ml/min, and aliquots from column fractions were 
analysed for immunoreactive α-hANF. Thereafter 
immunoreactive peaks were re-chromatographed on a 
Waters C18 μ-Bondapak reverse-phase column (39 x 
300 mm) and fractions assayed for α-hANF immunoreac-
tivity. 
Patient characteristics 
Blood was drawn from 41 normotensive control subjects 
who showed no evidence of cardiovascular, renal, 
pulmonary or gastrointestinal disease. Twenty-seven 
patients with essential hypertension were examined also; 
at the time of examination their mean blood pressure 
was 176 ± 4.1 (systolic) and 101 ± 35 (diastolic) mmHg. 
Thirteen hypertensive patients were either newly 
diagnosed or had discontinued their therapies. In 
addition, 14 patients with congestive heart failure [New 
York Heart Association (NYHA) stages II-IV] were studied 
also. Patients were hospitalized 1 week before 
catheterization of the heart and all medication was 
discontinued except for diuretics and digitalis. 
Measurements were taken before, immediately following 
and 6 months after institution of therapy with an 
angiotensin converting enzyme inhibitor (enalapril, 
usually 2 x 5 mg orally a day). Twenty patients with 
cirrhosis of the liver, confirmed by biochemical and 
histological examination, were investigated. Ascites was 
not evident in nine patients, moderate in five and severe 
in five. Ascitic patients were receiving spironolactone 
(100-400 mg orally a day). In five patients ANF 
measurements were reported after diuretic treatment 
had been discontinued for 4 days. All patients were on a 
hospital diet containing 150 mmol NaCl daily. 
Experimental protocols were approved by the 
institutional committee on the ethics of human 
investigation. 
Results 
Plasma levels of irANF for various clinical conditions are 
given in Table 1. Hypertensive patients on average 
displayed a sevenfold increase in plasma irANF compared 
with normotensive controls. A subgroup of untreated 
patients with essential hypertension had comparably high 
levels. 
Table 1. Plasma immunoreactivity of atrial natriuretic factor in 
various clinical conditions. 
Mean ± s.e.m. 
(fmol/ml) 
Normotensive controls (n = 41) 8.8 ± 1.1 
Hypertensive patients (n = 27) 62.2 ± 16.8** 
- untreated hypertension (n = 13; 
BP 188 ± 6/103 ± 4 mmHg) 51.0 ± 20.0** 
- treated hypertension, patients still 
hypertensive (n = 14; 
BP 168 ± 5/100 ± 5 mmHg) 73.0 ± 27.0** 
Patients with congestive failure heart (n = 14) 365 ± 133** 
Patients with cirrhosis of the liver (n = 19) 13.5 ± 1.3* 
Patients with pericardial tamponade (n = 4) 
- before puncture 34.2 ± 24.7 
- following puncture 297 ± 215 
Water immersion (n = 15) 
- before immersion 6.5 ± 0.8 
- during immersion 12.0 ± 2.6* 
- following immersion 6.1 ± 0.8 
*P < 0.02; **P < 0.001 (Student's unpaired t-test); Ψ < 0.01 
(Wilcoxon matched pairs test); BP, blood pressure. 
Patients with congestive heart failure (NYHA II-IV) 
displayed a 40-fold increase in plasma irANF. The 
relationship between the level of circulating irANF and 
cardiac performance was examined in more detail. 
Figure 1 shows plasma irANF levels plotted against mean 
right atrial pressure, mean pulmonary capillary wedge 
pressure and the cardiac index. Elevated plasma levels of 
irANF in patients with heart failure corresponded to 
increased atrial pressure and pulmonary capillary wedge 
pressure and were inversely related to the cardiac index. 
Haemodynamic parameters for patients with heart failure 
before and during treatment with the angiotensin 
converting enzyme inhibitor are given in Table 2. In 
parallel with the improvement in haemodynamic 
parameters, a statistically significant (P < 0.02, Wilcoxon 
paired-sample test) fall in plasma irANF to 43.8% of 
ANF in Plasma Arendt et at. 
(a) (b) (c) 
Cardiac index (l/mm per nrv) PC (mmHg) RA (mmHg) 
Fig. 1. Plasma levels of immunoreactive atrial natriuretic factor 
(ANF) are plotted versus (a) cardiac index (r = - 0 . 7 3 , Ρ < 0.01 ),(b) 
mean pulmonary capillary wedge (PC) pressure (r = 0.73, Ρ < 
0.01) and (c) mean right atrial (RA) pressure (r = 0.72, Ρ < 0.01) in 
patients with congestive heart failure. 
Table 2. Haemodynamics and plasma levels of atrial natriuretic 
factor (ANF) in patients with heart failure before and during enalapril 
therapy (n = 14). 
Before enalapril During enalapril 
Haemodynamics 
PC (mgHg) 
PAP (mmHg) 
RA (mmHg) 
MAP (mmHg) 
CI (l/min per m 2 ) 
HR (beats/min) 
ANF level (fmol/ml) (n 7) 
30 ± 3.9 
41 ± 4.1 
12 ± 1.5 
104 ± 4.4 
2.0 ± 0.1 
80 ± 3.9 
237 ± 133 
15 ± 3.1 
29 ± 3.9 
8 ± 1.3 
92 ± 3.6 
2.4 ± 0.2 
77 ± 3.1 
103 ± 64 
PC, mean pulmonary capillary wedge pressure; PAP, mean 
pulmonary arterial pressure; RA, mean right atrial pressure; MAP, 
mean arterial pressure; CI, cardiac index; HR, heart rate. Values are 
given as means ± s.e.m. 
pretreatment values (from 237 ± 133 to 104 ± 64 
fmol/ml) was seen in seven patients (remaining samples 
await analysis). 
Plasma levels of irANF in the cirrhotic group were 
slightly but significantly higher than in the control group 
(Table 1). Immunoreactive-ANF concentrations in the five 
patients with tense ascites ranged from 7.4 to 16.5 
fmol/ml and did not differ from those of the other 
cirrhotic patients. When spironolactone was discontin­
ued in five of the patients with ascites, an average 
increase of 47% was observed in irANF concentrations. 
The nature of the rise in ANF in hypertension was 
studied in more detail by characterization of the 
molecular-weight pattern of ANF in individual patients. 
By analysis of plasma extracts on high performance gel 
permeation chromatography (Fig. 2) and subsequent 
reverse-phase high performance liquid chromatography 
(Fig. 3), we had previously found that in normotensive 
individuals irANF consisted exclusively of authentic 
28-amino-acid α-hANF, the C-terminal portion of the 
human precursor pre-pro-ANF [11]. Chromatographic 
analysis of the plasma extracts of a still limited number of 
hypertensive patients revealed that irANF comprised a 
peak co-eluting with synthetic α-hANF as in normotensive 
subjects (Fig. 4). In the hypertensive patient shown on 
Fig. 4, both total irANF and 3100-dalton ANF were 
increased compared with normotensive controls. In 
fmol/tube 
> 15.0 -
£ 1 1 0 
QC 
Ο 
ζ 
5 6.6 -
5 
* 0.0 
τ π • • • rf-h-ANF I 
• 
Υτ 
20 30 40 
FRACTION NUMBER 
Fig. 2. Molecular weight pattern of immunoreactive atrial natriuretic 
factor (ANF) in plasma of a normotensive control subject on a 3.9 x 
300 mm TSK-125 Bio Sil high performance gel permeation 
chromatography system. Fraction aliquots were assayed for 
alpha-human ANF (α-h-ANF) immunoreactivity (from [10]). 
af-h-ANF 
I 
20 ζ 
Ο 
0 S 10 IS 20 25 30 35 40 45 50 
FRACTION NUMBER 
Fig. 3. Analysis by high performance liquid chromatography of 
α-human atrial natriuretic factor (α-h-ANF) from human plasma 
following high performance permeation chromatography (Fig. 2). 
The immunoreactive peak co-eluting with synthetic α-human atrial 
natriuretic factor on the high performance gel permeation 
chromatography system was re-chromatographed on a C18 
reverse-phase system and reassayed for α-human atrial natriuretic 
factor (from [10]). 
contrast to normotensive controls, Fig. 4 shows the 
presence of a higher molecular weight ANF precursor of 
c. 13 000 dalton. 
Discussion 
In conjunction with a novel extraction and purification 
procedure employing adsorbent resins, our radio­
immunoassay allows reliable detection of plasma irANF 
levels as low as 0.5 fmol/ml [10]. Plasma levels of irANF in 
healthy control subjects ranged from 1 to 23 fmol/ml. 
It has been hypothesized that failure to elaborate a 
natriuretic hormone adequately contributes to sodium 
retention and ascites formation in cirrhotic patients [12]. 
However, we found that irANF was slightly increased in 
cirrhotics in comparison with normotensive controls. 
Moreover, the increase in plasma irANF that we found 
after discontinuation of diuretic treatment suggests that 
Journal of Hypertension 1986, Vol 4 (suppl 2) 
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Fig. 4. Molecular weight pattern of immunoreactive atrial natriuretic 
factor (ANF) in the plasma of a hypertensive patient on a 3.9 χ 600 
mm TSK-125 Bio Sil high performance gel permeation chroma­
tography system. The column was calibrated with bovine serum 
albumin (V 0 ) , leu-enkephalin (VT) and a series of opioid peptides. 
Fraction aliquots were assayed for α-human ANF (α-hANF) 
immunoreactivity. Compared with Fig. 2 the separation power has 
been increased by reducing the solvent flow rate from 0.8 to 0.4 
ml/min. 
release of ANF is unimpaired in cirrhosis. It is possible, 
therefore, that despite the expanded extracellular 
volume in cirrhotics, splanchnic sequestration of fluids 
may prevent an increase in central volume and atrial 
pressure, and thus release may not be adequate to 
combat the volume overload. 
In contrast, patients with congestive heart failure have 
excessively elevated plasma levels of irANF. Elevations in 
plasma irANF concentrations in the present study were 
correlated with increases in right atrial and pulmonary 
capillary wedge pressure and were inversely related to 
cardiac index. While an accelerated release of ANF may 
be the physiological response to combat the volume 
overload in congestive heart failure, even a 40-fold 
increase in plasma irANF appears insufficient to reverse 
the clinical condition and may not improve symptomatol­
ogy. The problem may be caused by receptor 
down-regulation [13] or by conformational changes 
resulting in a decreased response of ANF target organs 
even in the presence of elevated plasma levels. On the 
other hand, defective enzymatic processing or increased 
metabolism may lead to high levels of irANF without 
corresponding physiological activity. In this context, it is 
interesting that, in a preliminary study, patients suffering 
from heart failure and with elevated plasma levels of 
irANF benefited haemodynamically from the acute 
administration of synthetic α-hANF as a therapeutic agent; 
however, no data on chronic application are currently 
available [14]. 
Although volume load and atrial pressure stimulate 
ANF release [8], patients with pericardial effusion and 
developing tamponade have comparably low irANF 
(Table 1) in spite of elevated atrial and ventricular 
pressures. In the present study, plasma concentrations of 
irANF rose markedly following pericardial decompres­
sion (Table 1). This indicates that increased pressure 
alone may not be the only stimulus for ANF release. 
Severe heart failure has of late been treated by 
angiotensin converting enzyme inhibitors. The beneficial 
effect of these inhibitors in congestive heart failure may 
be explained by a reduction in angiotensin II levels, but 
they are also associated with a reduction in circulating 
catecholamines, a decrease in antidiuretic hormone 
production and a reduction in aldosterone levels [15]. 
These factors may lead to the clinical improvement of 
patients and secondarily to a reduction in ANF release. 
The greatest variability in plasma irANF levels was seen 
among hypertensive patients and ranged from normal to 
excessively elevated. The pathyophysiological role of ANF 
in pressure regulation, and in 'pressure-diuresis', 
remains to be elucidated. Preliminary chromatographic 
data do not rule out the possibility that plasma ANF 
circulates in different molecular forms [16] and that 
differences in synthesis and enzymatic processing or 
metabolism may be involved in the pathophysiology of 
hypertension. 
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